House lawmakers hear mixed views on credentialing for psychedelic providers

As psychedelic medicines move closer to market, two members of the U.S. House are outlining how the drugs might be rolled out and what accompanying legislation could look like.

The focus of their hearing is on how providers of psychedelic therapies should be credentialed. Experts offered divergent views, with some urging clear standards to protect patients and others warning that overly strict rules could limit access.

The mixed feedback highlights the need for a regulatory framework as psychedelics become commercially available, but lawmakers have yet to reach agreement on the details.